DNA-based vaccination for the treatment of food allergy.
DNA-based vaccination for the treatment of food allergy.
复制标题
基于 DNA 的疫苗接种用于治疗食物过敏。
DOI：
10.1034/j.1398-9995.2001.00937.x
复制
发表时间：
2001
期刊：
影响因子：
12.4
通讯作者：
Horner,AA
中科院分区：
文献类型：
--
作者：
Nguyen,MD;Cinman,N;Yen,J;Horner,AA
目前，对于对食物过敏的个人来说，避免食用是唯一可用的治疗选择。然而，研究表明，基于DNA的疫苗接种可能是逆转过敏反应(包括对食物过敏)的有效治疗选择。由于严重的过敏反应对食物过敏患者有生命危险，我们和其他人评估了基于DNA的疫苗在小鼠模型中预防过敏反应的有效性。我们的研究表明，Th2致敏小鼠的初级基因和蛋白质/免疫刺激序列寡核苷酸(ISS-ODN)疫苗显著降低了过敏攻击后的死亡风险。此外，基因和蛋白质/ISS-ODN疫苗接种降低了攻击后血浆组胺水平。对接受DNA疫苗的小鼠的免疫图谱分析表明，基因和蛋白质/ISS-ODN疫苗都有效地阻止了致敏后以Th2为基础的免疫图谱的形成。相比之下，单独接种蛋白质疫苗，即临床上使用的传统基于蛋白质的免疫治疗(IT)试剂的实验等价物，没有提供过敏反应的保护，也没有防止过敏原致敏后出现Th2偏向的免疫图谱。这些研究证明，人们对基于DNA的疫苗用于食物过敏患者脱敏的潜力仍然持乐观态度。
At present, avoidance is the only therapeutic option available for individuals with food allergies. However, studies suggest that DNA‐based vaccination might be an effective therapeutic option for the reversal of allergic hypersensitivities, including allergies to foods. Because severe anaphylactic reactions represent a life‐threatening risk for individuals with food allergies, we and others have evaluated the effectiveness of DNA‐based vaccination for the prevention of anaphylactic hypersensitivity in murine models. Our investigations demonstrated that primary gene and protein/immunostimulatory sequence oligodeoxynucleotide (ISS‐ODN) vaccination of subsequently Th2‐sensitized mice reduced the risk of death after anaphylactic challenge, significantly. In addition, gene and protein/ISS‐ODN vaccination reduced post challenge plasma histamine levels. Analysis of the immune profiles of mice receiving DNA‐based vaccines showed that both gene and protein/ISS‐ODN vaccination effectively prevented the development of Th2‐biased immune profiles after sensitization. In contrast, vaccination with protein alone, the experimental equivalent of the traditional protein‐based immunotherapy (IT) reagents used in clinical practice provided no protection from anaphylaxis, nor did it prevent the development of a Th2‐biased immune profile after allergen sensitization. These studies justify continued optimism in the potential of DNA‐based vaccination for the desensitization of food allergic individuals.